(Press-News.org) CHICAGO, IL — Treatment with the diabetes drug liraglutide, in combination with diet and exercise, led to a significant reduction in weight and improved a number of cardiovascular risk factors, including high blood pressure and high cholesterol, according to a multicenter study. The results, from more than 3,700 overweight and obese nondiabetic adults, were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
"If these improvements continue over time, they may result in a lower risk of heart disease," said the study's principal investigator, Carel Le Roux, MD, PhD, Diabetes Complications Research Centre, University College Dublin.
The drug is undergoing testing at a 3 milligram (mg) dose for long-term weight management as part of the SCALE™ (Satiety and Clinical Adiposity—Liraglutide Evidence in Nondiabetic and Diabetic Subjects) Obesity and Prediabetes trial. Liraglutide currently is marketed as Victoza® in 1.2 mg and 1.8 mg injectable doses for adults with Type 2 diabetes to help control blood glucose (sugar) when used along with diet and exercise. The drug does not have approval for weight loss, according to its manufacturer, Denmark-headquartered Novo Nordisk, which sponsored the study.
The study included 3,731 nondiabetic obese adults and overweight adults who had at least one other risk factor for diabetes and heart disease, such as prediabetes, high blood pressure or high cholesterol. As part of the study's weight loss efforts, all subjects exercised and ate 500 fewer calories per day than usual. In addition, they were randomly assigned, in a 2-to-1 ratio, to a once-daily injection with either 3 mg of liraglutide (2,487 subjects) or placebo (1,244 subjects) for 56 weeks. Neither the subjects nor the investigators knew who received the active drug.
On average, individuals treated with liraglutide 3 mg lost 5.4 percent more of their body weight, achieving a total of 8 percent, and nearly 1.7 more inches (4.2 centimeters) around their waist than did those who received placebo, the investigators reported.
Compared with the placebo group, liraglutide-treated subjects also experienced better improvements in blood pressure and levels of all fasting lipids (blood fats), including LDL ("bad") cholesterol, HDL ("good") cholesterol, triglycerides and total cholesterol, according to Le Roux. These improvements, he said, resulted in a greater reduction in net use of blood pressure drugs and lipid-lowering medications in the liraglutide 3 mg group than in the placebo group.
In general, the researchers found liraglutide 3 mg to have a safety profile that was similar to that found in previous clinical trials of the drug in individuals with Type 2 diabetes treated with lower doses.
"Current obesity treatment options are limited," Le Roux said. "There is a need for new treatment options for people who struggle with obesity and obesity-related diseases that can help in reducing their weight."
INFORMATION:
Founded in 1916, the Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society's membership consists of over 17,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
Diabetes drug, Liraglutide, improves risk factors for heart disease
2014-06-23
ELSE PRESS RELEASES FROM THIS DATE:
BUSM researchers investigating ways to improve type 2 diabetes treatments
2014-06-23
(Boston) – A better understanding of how the transcription factor Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) works is critical to find new ways to improve medications to treat type 2 diabetes. Drugs that activate PPARgamma, called thiazolidinediones (TZDs), have long been regarded as a treatment for type 2 diabetes based on their anti-inflammatory and potent insulin-sensitizing activity. When taken orally, TZDs help decrease insulin resistance. However, most medications in that class have now been withdrawn from the market, or severely limited in their ...
#Sexychem: 4 ways chemistry makes sex safe -- and spicy (video)
2014-06-23
WASHINGTON, June 23, 2014 — In this week's episode, Reactions is getting sexy. Our latest video highlights the ways chemistry has made sex safer and (in one surprising case) spicier. From latex condoms to warming lubricants, birth control to emergency contraception, chemistry plays a big role in the bedroom, and not just the chemistry between you and your partner. The video is available at http://youtu.be/54-rMC_67TM.INFORMATION:
Subscribe to the series at Reactions YouTube, and follow us on Twitter @ACSreactions to be the first to see our latest videos.
The American ...
Long non-coding RNAs can encode proteins after all
2014-06-23
Case Western Reserve School of Medicine scientists have made an extraordinary double discovery. First, they have identified thousands of novel long non-coding ribonucleic acid (lncRNA) transcripts. Second, they have learned that some of them defy conventional wisdom regarding lncRNA transcripts, because they actually do direct the synthesis of proteins in cells.
Both of the breakthroughs are detailed in the June 12 issue of Cell Reports.
Kristian E. Baker, PhD, assistant professor in the Center for RNA Molecular Biology, led the team that applied high throughput gene ...
Exposure to BPA substitute causes hyperactivity and brain changes in fish
2014-06-23
CHICAGO, IL — A chemical found in many "BPA free" consumer products, known as bisphenol S (BPS), is just as potent as bisphenol A (BPA) in altering brain development and causing hyperactive behavior, an animal study finds. The results will be presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
BPA has been linked to a wide range of hormone disorders, such as obesity, reproductive cancers and, recently, hyperactivity in children born to women exposed to high levels of this substance during ...
BPA stimulates growth of breast cancer cells, diminishes effect of treatment
2014-06-23
DURHAM, N.C. – Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at an annual meeting of endocrine scientists.
The researchers found that the chemical, at levels typically found in human blood, could also affect growth of an aggressive hormone-independent subtype of breast cancer cells called inflammatory breast cancer and diminish the effectiveness of treatments for the disease.
"We set out to determine whether routine exposures to common chemicals ...
Hormone-disrupting activity of fracking chemicals worse than initially found
2014-06-23
CHICAGO, IL—Many chemicals used in hydraulic fracturing, or fracking, can disrupt not only the human body's reproductive hormones but also the glucocorticoid and thyroid hormone receptors, which are necessary to maintain good health, a new study finds. The results were presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
"Among the chemicals that the fracking industry has reported using most often, all 24 that we have tested block the activity of one or more important hormone receptors," ...
Common BPA-like chemical, BPS, disrupts heart rhythms in females
2014-06-23
CHICAGO, IL—Bisphenol S (BPS), a common substitute for bisphenol A (BPA) in consumer products, may have similar toxic effects on the heart as previously reported for BPA, a new study finds. The results were presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
In the years since research evidence first showed many potentially damaging health effects of the industrial chemical BPA, some manufacturers have switched to its chemical cousin, BPS, to make hard plastics and other products that ...
Researchers synthesize previously unknown form of magnesium carbide
2014-06-23
An international team of researchers from the United States, France and Moscow Institute of Physics and Technology (Russia) has synthesized a previously unknown form of magnesium carbide. This material can be used for synthesizing carbon nanostructures and other compounds. Details can be found in an article published in the journal Inorganic Chemistry.
A team of researchers from the Carnegie Institution for Science (United States), Paris-Sorbonne University, the European Synchrotron Radiation Facility in Grenoble,the SOLEIL synchrotron facility (France), the State University ...
Electrostatics do the trick
2014-06-23
Organic semiconductors allow for flexible displays (OLEDs), solar cells (OPVCs), and other interesting applications. One common problem in these devices, however, is the interface between the metallic contacts and the organic semiconductor material, where undesirable losses occur. Now Dr. Martin Oehzelt has shown what these losses between the metal and the organic semiconductors depend upon and how to minimize them. In particular, his model also explains why a thin, electrically insulating layer between the two materials can even facilitate the transition of charge carriers. ...
New study offers potential avenues for treatment of deadly nasopharyngeal cancer
2014-06-23
A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, National University Cancer Institute Singapore (NCIS) and National University Hospital Singapore (NUH), discovered a distinct mutational signature and nine significantly mutated genes associated with nasopharyngeal cancer, paving the way to developing novel therapies for this deadly disease.
The research group, led by Professor H. Phillip Koeffler, Senior Principal Investigator at the CSI Singapore and Deputy Director of NCIS, has conducted the ...